You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 60 No. 2, February 2003 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (68)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Neurology
 •Cognitive Disorders
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Serum Anticholinergic Activity in a Community-Based Sample of Older Adults

Relationship With Cognitive Performance

Benoit H. Mulsant, MD; Bruce G. Pollock, MD, PhD; Margaret Kirshner, BA; Changyu Shen, BS; Hiroko Dodge, PhD; Mary Ganguli, MD

Arch Gen Psychiatry. 2003;60:198-203.

Background  Serum anticholinergic activity (SAA), as measured by a radioreceptor assay, quantifies a person's overall anticholinergic burden caused by all drugs and their metabolites. In several small geriatric patient groups, SAA has been associated with cognitive impairment or frank delirium. To our knowledge, there has not yet been any systematic study of the prevalence of SAA and its effect on cognition in a community-based population.

Methods  Serum anticholinergic activity was measured in 201 subjects who were randomly selected among the participants in an epidemiological community study, based on their age and sex. Cognitive performance was assessed with use of the Mini-Mental State Examination. The association between SAA and cognitive performance was examined using a univariate analysis and a multiple logistic regression model, adjusting for age, sex, educational level, and number of medications.

Results  Serum anticholinergic activity was detectable in 180 (89.6%) participants (range, 0.50-5.70 pmol/mL). Univariate testing showed a significant association between SAA and Mini-Mental State Examination scores. Logistic regression analysis indicated that subjects with SAA at or above the sample's 90th percentile (ie, SAA >=2.80 pmol/mL) were 13 times (odds ratio, 1.08-152.39) more likely than subjects with undetectable SAA to have a Mini-Mental State Examination score of 24 (the sample's 10th percentile) or below.

Conclusions  To our knowledge, this is the largest analysis of SAA and the first to examine its extent and relationship with cognitive performance in a community sample. Its results suggest that SAA can be detected in most older persons in the community and confirm that even low SAA is associated with cognitive impairment.


From the Department of Psychiatry, University of Pittsburgh School of Medicine (Drs Mulsant, Pollock, and Ganguli and Ms Kirshner), Geriatric Research, Education, and Clinical Center, VA Pittsburgh Healthcare System (Dr Mulsant), and Departments of Biostatistics (Dr Dodge and Mr Shen) and Epidemiology (Dr Ganguli), University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pa. These authors have or have had a financial interest, an arrangement, or an affiliation with the following: Forest Pharmaceuticals, Inc, GlaxoSmithKline, Pfizer, Inc/Eisai, Janssen Pharmaceutica, and H. Lundbeck (Drs Mulsant and Pollock); AstraZeneca, Corcept, Eli Lilly, Akzo-Nobel, Alkermes, Biogen, Celsion, Elan, and Immune Response (Dr Mulsant); and Pharmacia & Upjohn and Organon Inc (Dr Pollock).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Anticholinergic Activity of Commonly Prescribed Medications and Neuropsychiatric Adverse Events in Older People
Nishtala et al.
J Clin Pharmacol 2009;49:1176-1184.
ABSTRACT | FULL TEXT  

The Cognitive Cost of Anticholinergic Burden: Decreased Response to Cognitive Training in Schizophrenia
Vinogradov et al.
Am. J. Psychiatry 2009;166:1055-1062.
ABSTRACT | FULL TEXT  

Drugs With Anticholinergic Properties, Cognitive Decline, and Dementia in an Elderly General Population: The 3-City Study
Carriere et al.
Arch Intern Med 2009;169:1317-1324.
ABSTRACT | FULL TEXT  

Ask the Expert: Psychosomatic Medicine/Delirium
Maldonado
Focus 2009;7:336-342.
FULL TEXT  

Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches
Agar et al.
Palliat Med 2009;23:257-265.
ABSTRACT  

Self-Reported Sleep Quality Predicts Poor Cognitive Performance in Healthy Older Adults
Nebes et al.
J Gerontol B Psychol Sci Soc Sci 2009;64B:180-187.
ABSTRACT | FULL TEXT  

Exposure to secondhand smoke and cognitive impairment in non-smokers: national cross sectional study with cotinine measurement
Llewellyn et al.
BMJ 2009;338:b462-b462.
ABSTRACT | FULL TEXT  

Use of drugs with anticholinegic effects and cognitive impairment in community-living older persons
Merchant et al.
Age Ageing 2009;38:105-108.
FULL TEXT  

A 60-Year-Old Woman With Mild Memory Impairment: Review of Mild Cognitive Impairment
Ellison
JAMA 2008;300:1566-1574.
ABSTRACT | FULL TEXT  

The Anticholinergic Risk Scale and Anticholinergic Adverse Effects in Older Persons
Rudolph et al.
Arch Intern Med 2008;168:508-513.
ABSTRACT | FULL TEXT  

Mild Cognitive Dysfunction: An Epidemiological Perspective With an Emphasis on African Americans
Unverzagt et al.
J Geriatr Psychiatry Neurol 2007;20:215-226.
ABSTRACT  

Heart Rate Variability in Patients With Depression
Jindal and Keshavan
Arch Gen Psychiatry 2007;64:611-612.
FULL TEXT  

A Drug Burden Index to Define the Functional Burden of Medications in Older People
Hilmer et al.
Arch Intern Med 2007;167:781-787.
ABSTRACT | FULL TEXT  

Serum Anticholinergic Activity and Motor Performance in Elderly Persons
Nebes et al.
J Gerontol A Biol Sci Med Sci 2007;62:83-85.
ABSTRACT | FULL TEXT  

Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study
Ancelin et al.
BMJ 2006;332:455-459.
ABSTRACT | FULL TEXT  

Perspectives on Depression, Mild Cognitive Impairment, and Cognitive Decline
Steffens et al.
Arch Gen Psychiatry 2006;63:130-138.
ABSTRACT | FULL TEXT  

Serum anticholinergic activity, white matter hyperintensities, and cognitive performance
Nebes et al.
Neurology 2005;65:1487-1489.
ABSTRACT | FULL TEXT  

Aging and Clinical Pharmacology: Implications for Antidepressants
Lotrich and Pollock
J Clin Pharmacol 2005;45:1106-1122.
ABSTRACT | FULL TEXT  

Delirium in Elderly Patients
Cole
Focus 2005;3:320-332.
ABSTRACT | FULL TEXT  

Physical Activity, Including Walking, and Cognitive Function in Older Women
Weuve et al.
JAMA 2004;292:1454-1461.
ABSTRACT | FULL TEXT  

The Nature and Determinants of Neuropsychological Functioning in Late-Life Depression
Butters et al.
Arch Gen Psychiatry 2004;61:587-595.
ABSTRACT | FULL TEXT  

Delirium and Dementia
Ajilore and Kumar
Focus 2004;2:210-220.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.